Rigel Pharmaceuticals Inc
RIGL· Nasdaq
RIGLRigel Pharmaceuticals Inc
Released Nov 7, 2024, after the close
10-Q filed Nov 7, 2024, 38 days after period end · 0001558370-24-014862
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Revenue | $55.31M | $28.13M | $22.41M | $21.54M |
| Net Income | $12.42M | -$5.69M | -$19.04M | -$20.95M |
| EPS Diluted |
Rigel Pharmaceuticals Inc · CIK 1034842 · Engraved from SEC EDGAR
| $0.70 |
| -$0.33 |
| -$0.11 |
| -$0.12 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
